38104-45-9

Usage

InChI:InChI=1/C2H5N5/c3-2-6-5-1-7(2)4/h1H,4H2,(H2,3,6)

Upstream product

• 64-18-6 formic acid 
• 10308-83-5 N,N'-diamino-guanidine; nitrate 
• 3529-50-8 4,5-diamino-2,4-dihydro-[1,2,4]triazole-3-thione 
• 23160-99-8 3,4-diamino-1,2,4-triazole hydrobromide 
• 6421-05-2 3,4-diamino-4H-1,2,4-triazole hydrochloride 

Downstream Products

• 37160-06-8 6,7-diphenyl-[1,2,4]triazolo[4,3-b][1,2,4]triazine 
• 141228-31-1 4-(5,6-dihydro-7H-1,2,4-triazolo<4,3-b>-1,2,4-triazol-6-ylidene)-2,4-dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one 
• 71347-44-9 7-(4-fluoro-phenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazine 
• 71347-43-8 7-(4-methoxy-phenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazine 
• 71347-46-1 7-(2-chloro-phenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazine 
• 1491137-09-7 C₂H₅N₅*C₂H₂N₄O₃ 
• 71347-45-0 7-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazine 

Relevant academic research and scientific papers

Syntheses, crystal structures and thermal analyses of two new ionic complexes based on 3,4-diamino-1,2,4-triazole

Two new ionic complexes, (DATr)2[Li2(TNR)2·2H2O]·2H2O (1) and (DATr)[Zn(DATr)Cl3] (2), were synthesized by using 3,4-diamino-1,2,4-triazole (DATr) as outer cation. X-ray single-crystal diff

Energetic oxygen-containing tetrazole salts based on 3,4-diaminotriazole

Energetic mono- and dicationic 3,4-diaminotriazolium salts have been prepared by combining stoichiometric amounts (1:1 or 2:1 molar ratio) of 3,4-diaminotriazole with various oxygen-containing tetrazoles, and the structures have been confirmed by single-crystal XRD for the first time. All structures are dominated by a strong hydrogen-bond network owing to both amino groups and oxygen in the molecule. All salts, except 7, exhibit excellent thermal stabilities with decomposition temperatures over 200C. Based on experimental densities and theoretical calculations carried out by using the Gaussian 03 suite of programs, all salts have calculated detonation pressures (20.3-33.9 GPa) and velocities (7095-8642 ms-1).

Synthesis, characterization, and thermal analysis of two energetic Ionic Salts based on 3,4-Diamino-1,2,4-triazole (DATr)

Two energetic ionic salts DATr·NTO (2) and DATr·TNR (3) of 3,4-diamino-1,2,4-triazole (DATr) (1) were synthesized by reaction of 3,4-diamino-1,2,4-triazole with either 3-nitro-1,2,4-triazole-5-one (NTO) or 2,4,6-trinitro-resorcinol (TNR) in aqueous soluti

Heteropolycyclic inhibitors of protein kinases

A compound of the formula wherein, independently at each occurrence, v, w, and x are selected from C, N, O, and S, with H substitution as needed to fulfill open valence sites; y and z are selected from N and C, with H substitution as needed to fulfill open valence sites, with the proviso that each of w, v, x, y and z is not simultaneously C; the ring formed from v, w, x, y and z may be saturated or unsaturated; and R1, R2, R3and R4are selected from hydrogen, alkyl, aryl, alkaryl, aralkyl, heteroalkyl, and heteroaryl; wherein any adjacent two of R1, R2, R3and R4may join together to form a 5, 6 or 7-membered carbocyclic or heterocyclic ring, with the proviso that each of R1, R2, R3and R4is not simultaneously hydrogen. Pharmaceutical compositions of said compounds, and methods of use in the treatment of biological conditions including cellular hyperproliferation, are disclosed.

Heteropolycyclic inhibitors of protein kinases

A compound of the formula wherein, independently at each occurrence, v, w, and x are selected from C, N, O, and S, with H substitution as needed to fulfill open valence sites; y and z are selected from N and C, with H substitution as needed to fulfill open valence sites, with the proviso that each of w, v, x, y and z is not simultaneously C; the ring formed from v, w, x, y and z may be saturated or unsaturated; and R1, R2, R3 and R4 are selected from hydrogen, alkyl, aryl, alkaryl, aralkyl, heteroalkyl, and heteroaryl; wherein any adjacent two of R1, R2, R3 and R4 may join together to form a 5, 6 or 7-membered carbocyclic or heterocyclic ring, with the proviso that each of R1, R2, R3 and R4 is not simultaneously hydrogen. Pharmaceutical compositions of said compounds, and methods of use in the treatment of biological conditions including cellular hyperproliferation, are disclosed.